A jury voted in favor of Amgen ( AMGN) Tuesday in a patent dispute case, according to a Bloomberg report.

The ruling determines in effect that Roche may not sell Mircera, its rival medicine to Amgen's Aranesp and Epogen anemia drugs, in the U.S.

Amgen shares were rising 87 cents, or 1.6%, to $56.99 in recent trading.